Down -32.76% in 4 Weeks, Here's Why Biohaven Ltd. (BHVN) Looks Ripe for a TurnaroundZacks Investment Research • 05/13/24
Biohaven Reports First Quarter 2024 Financial Results and Recent Business DevelopmentsPRNewsWire • 05/09/24
Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business UpdatesPRNewsWire • 04/13/24
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business DevelopmentsPRNewsWire • 02/29/24
Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and OncolPRNewsWire • 01/08/24
Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual MeetingPRNewsWire • 12/01/23
Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 11/16/23
Biohaven Reports Third Quarter 2023 Financial Results and Recent Business DevelopmentsPRNewsWire • 11/14/23
Biohaven Ltd. (BHVN) Is a Great Choice for 'Trend' Investors, Here's WhyZacks Investment Research • 11/06/23
Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®PRNewsWire • 10/16/23
Biohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29%Investors Business Daily • 09/27/23
Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular AtrophyPRNewsWire • 09/14/23